Article Versions Notes

Mollica V, Brocchi S, Dall’Olio FG, Marcolin L, Paccapelo A, Santoni M, Rizzo A, Montironi R, Golfieri R, Massari F, et al. Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough. Cancers. 2021; 13(14):3492. https://doi.org/10.3390/cancers13143492

Mollica, Veronica, Stefano Brocchi, Filippo Gustavo Dall’Olio, Laura Marcolin, Alexandro Paccapelo, Matteo Santoni, Alessandro Rizzo, Rodolfo Montironi, Rita Golfieri, Francesco Massari, and et al. 2021. "Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough" Cancers 13, no. 14: 3492. https://doi.org/10.3390/cancers13143492

Mollica, V., Brocchi, S., Dall’Olio, F. G., Marcolin, L., Paccapelo, A., Santoni, M., Rizzo, A., Montironi, R., Golfieri, R., Massari, F., & Ardizzoni, A. (2021). Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough. Cancers, 13(14), 3492. https://doi.org/10.3390/cancers13143492